Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Jul 15, 2020; 12(7): 756-767
Published online Jul 15, 2020. doi: 10.4251/wjgo.v12.i7.756
Published online Jul 15, 2020. doi: 10.4251/wjgo.v12.i7.756
Table 1 Comparison of clinicopathologic and perioperative variables by hyperthermic intraperitoneal chemotherapy technique
| Open | Closed | P value | ||||
| n = 372 | n = 1440 | |||||
| n (%) | n (%) | |||||
| Female gender | 165 (44.4) | 616 (42.8) | 0.58 | |||
| Mean age (SD) | 52.7 (12.4) | 54.6 (12.4) | 0.02 | |||
| Race | < 0.01 | |||||
| White | 350 (94.1) | 1140 (79.2) | ||||
| Black | 16 (4.3) | 83 (5.8) | ||||
| Asian | 2 (0.5) | 79 (5.5) | ||||
| Latino | 0 (0) | 71 (4.9) | ||||
| Other | 4 (1.1) | 50 (3.5) | ||||
| Missing | 0 (0) | 17 (1.2) | ||||
| Mean BMI (SD) | 28.4 (6.6) | 27.9 (6.6) | 0.22 | |||
| Previous CRS | < 0.01 | |||||
| 0 | 328 (88.1) | 1088 (75.6) | ||||
| 1 | 38 (10.2) | 298 (20.7) | ||||
| 2+ | 5 (1.3) | 51 (3.5) | ||||
| Missing | 1 (0.3) | 3 (0.2) | ||||
| Mean preoperative albumin (SD) | 4.0 (0.5) | 4.1 (0.5) | 0.17 | |||
| Histology | < 0.01 | |||||
| Appendiceal | 311 (83.6) | 870 (60.4) | ||||
| Colorectal | 42 (11.3) | 376 (26.1) | ||||
| Mesothelioma | 9 (2.4) | 142 (9.9) | ||||
| Other | 10 (2.7) | 52 (3.6) | ||||
| Tumor differentiation (appendiceal and colorectal) | < 0.01 | |||||
| Well | 214 (60.6) | 647 (51.9) | ||||
| Moderate or poor | 105 (29.8) | 511 (41.0) | ||||
| Missing | 34 (9.6) | 88 (7.1) | ||||
| ASA grade | < 0.01 | |||||
| 1 / 2 | 26 (7.0) | 249 (17.3) | ||||
| 3 / 4 | 346 (93.0) | 1024 (71.1) | ||||
| Missing | 0 (0) | 167 (11.6) | ||||
| Mean PCI (SD) | 10.8 (14.7) | 14.7 (8.7) | < 0.01 | |||
| Neoadjuvant chemotherapy | 0.47 | |||||
| Yes | 129 (34.7) | 508 (35.3) | ||||
| No | 239 (64.3) | 925 (64.2) | ||||
| Missing | 4 (1.1) | 7 (0.5) | ||||
| Mean operative time (h) (SD) | 6.7 (2.1) | 8.5 (2.7) | < 0.01 | |||
| Mean estimated blood loss (cc) (SD) | 491 (931) | 444 (560) | 0.37 | |||
| IP chemotherapy | 0.05 | |||||
| Mitomycin-C | 352 (94.6) | 1299 (90.2) | ||||
| Cisplatin | 14 (3.8) | 90 (6.3) | ||||
| Other | 6 (1.6) | 51 (3.5) | ||||
| Median MMC dose (mg) (IQR) | 54 (40-60) | 40 (33-40) | < 0.01 | |||
| Median cisplatin dose (mg) (IQR) | 75 (58-110) | 138 (86-250) | < 0.01 | |||
| Target temperature 40-43 ˚C | 362 (97.3) | 1415 (98.3) | 0.25 | |||
| Mean HIPEC duration (min) (SD) | 87 (10) | 89 (8) | 0.14 | |||
| CCR | < 0.01 | |||||
| CC 0/1 | 316 (84.9) | 1263 (87.7) | ||||
| CC 2/3 | 53 (14.2) | 74 (5.1) | ||||
| Missing | 3 (0.8) | 103 (7.2) | ||||
| Median LOS (IQR) | 9 (8-13) | 10 (8-13) | 0.50 | |||
| Complications | 0.27 | |||||
| Grade 0-II | 306 (82.3) | 1146 (79.6) | ||||
| Grade III-V | 66 (17.7) | 294 (20.4) | ||||
| 90-d readmission | < 0.01 | |||||
| Yes | 47 (12.6) | 341 (23.7) | ||||
| No | 321 (86.3) | 1089 (75.6) | ||||
| Missing | 4 (1.1) | 10 (0.7) | ||||
| Re-operation | 32 (8.6) | 131 (9.1) | 0.59 | |||
| Median days in ICU (IQR) | 2 (2-3) | 1 (0-3) | < 0.01 | |||
| 90-d mortality | 14 (3.8) | 25 (1.7) | 0.03 | |||
| Adjuvant chemotherapy | < 0.01 | |||||
| Yes | 47 (12.6) | 341 (23.7) | ||||
| No | 323 (86.8) | 1095 (76.0) | ||||
| Missing | 2 (0.5) | 4 (0.3) | ||||
- Citation: Leiting JL, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dessureault S, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Zaidi MY, Patel SH, Ahmad SA, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, LaRocca CJ, Johnston FM, Greer J, Grotz TE. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J Gastrointest Oncol 2020; 12(7): 756-767
- URL: https://www.wjgnet.com/1948-5204/full/v12/i7/756.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i7.756